PTG Poltreg S.A.

GPW · PL · Healthcare · Biotechnology · poltreg.bio

20.00PLN-1.48%Mkt Cap: 30.42M $P/E: —Today

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap30.42M USD

Enterprise Value26.58M USD

Revenue (TTM)60.78K USD

Gross Profit-1.36M USD

Net Income (TTM)-6.58M USD

Revenue/Share0.05 PLN

Last Price20.00 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees34

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLPLTRG00038

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-5.46

EV/Revenue437.25

P/S500.43

P/B2.47

EPS (TTM)-4.98

EPS (Forward)—

52W Range

16.0020% of range36.00

52W High36.00 PLN

52W Low16.00 PLN

Profitability

Gross Margin0.00%

Oper. Margin-2313.33%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-60.00%

ROA-35.64%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-7.06M USD

CapEx (TTM)137.52K USD

FCF Margin-5975.78%

FCF Yield-11.94%

Net Debt-3.84M USD

Net Debt/EBITDA0.79

Balance Sheet

Debt/Equity0.18

Current Ratio3.49

Quick Ratio3.30

Book Value/Sh8.23 PLN

Cash/Share3.83 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.5.92M

Float3.83M

Insiders32.43%

Institutions29.26%

Technical

SMA 5023.38 (-14.5%)

SMA 20022.07 (-9.4%)

Beta0.82

S&P 52W Chg14.58%

Avg Vol (30d)6.49K

Avg Vol (10d)5.32K

Technical Indicators

RSI (14)47.0

MACD0.3889

MACD Signal0.7853

MACD Hist.-0.3963

BB Upper26.56 PLN

BB Middle21.42 PLN

BB Lower16.28 PLN

BB Width47.98%

ATR (14)1.429 PLN

Vol Ratio (20d)0.18x